Skip to main content

Advertisement

SpringerLink
Log in

Effects of a Combined Mitochondria-Targeted Treatment on the State of Mitochondria and Synaptic Membranes from the Brains of Diabetic Rats

  • Published:
Neurophysiology Aims and scope

On samples of the mitochondria and synaptic membranes isolated from rat brains using differential centrifugation, we tried to evaluate the neuroprotective efficacy of a combination of mitochondriaspecific antioxidants, acetyl-L-carnitine (ALC) and α-lipoic acid (LA), with nicotinamide (NAm), against diabetes-induced disorders in the CNS. Three groups of adult male Wistar rats were examined; these were control intact rats (group C), animals with experimental streptozotocin (STZ)-induced diabetes (group D; 6 weeks after STZ injections), and diabetic rats treated during the two final weeks of the above period by a combination of ALC, LA, and NAm (separate daily injections; doses 100, 50, and 100 mg/kg body mass, respectively; group D+T). At the day of preparation of the organelle samples, the mean blood glucose levels in groups C, D, and D+T were 4.8, 20.3, and 15.4 mM, respectively. The intensity of reactive oxygen species (ROS) production in the brain mitochondria from rats of group D measured by fluorescent analyses using 2’,7’-dichlorofluorescein diacetate was, on average, 37.2% greater than that in group C. Co-treatment provided a significant decrease in the above index in group D+T (27.8% in comparison with group D). Diabetes led to dramatic intensification of the CYP2E1 protein level in the liver of group D animals (242% vs. group C). In group D+T, this index was 33.1% lower than that in group D.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. S. T. Jerram and R. D. Leslie, “The genetic architecture of type 1 diabetes,” Genes, 8, No. 8, 209 (2017), doi:https://doi.org/10.3390/genes8080209.

    Article  CAS  PubMed Central  Google Scholar 

  2. M. Rewers, H. Hyöty, A. Lernmark, et al., “The environmental determinants of diabetes in the young (TEDDY) study: 2018 update,” Curr. Diab. Rep., 18, No. 12, 136 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  3. K. A. Adeshara, A. G. Diwan, and R. S. Tupe, “Diabetes and complications: Cellular signaling pathways, current understanding and targeted therapies,” Curr. Drug Targets, 17, No. 11, 1309–1328 (2016).

    Article  CAS  PubMed  Google Scholar 

  4. V.R. Drel, P. Pacher, R. Stavniichuk, et al., “Poly(ADPribose) polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice,” Int. J. Mol. Med., 28, No. 4, 629–635 (2011).

    CAS  PubMed  Google Scholar 

  5. W. Li, E. Huang, and S. Gao, “Type 1 diabetes mellitus and cognitive impairments: A systematic review,” J. Alzheimers Dis., 57, No. 1, 29–36 (2017).

    Article  CAS  PubMed  Google Scholar 

  6. S. A. Hamed, “Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications,” Expert Rev. Clin. Pharmacol., 10, No. 4, 409–428 (2017).

    Article  CAS  PubMed  Google Scholar 

  7. I. Trikash, V. Gumenyuk, and T. Kuchmerovska, “Diabetes-induced impairments of the exocytosis process and effect of gabapentin: the link with cholesterol level in neuronal plasma membranes,” Neurochem. Res., 40, No. 4, 723–732 (2015).

    Article  CAS  PubMed  Google Scholar 

  8. E. Blázquez, E. Velázquez, V. Hurtado-Carneiro, and J.M. Ruiz-Albusac, “Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer’s disease,” Front. Endocrinol., 5, 161 (2014), doi:https://doi.org/10.3389/fendo.2014.00161.

    Article  Google Scholar 

  9. J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic complications,” Physiol. Rev., 93, No. 1, 137–188 (2013).

    Article  CAS  PubMed  Google Scholar 

  10. S. Dewanjee, S. Das, A.K. Das, et al., “Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets,” Eur. J. Pharmacol., 833, 472–523 (2018).

    Article  CAS  PubMed  Google Scholar 

  11. A. Verkhratsky, M. Trebak, F. Perocchi, et al., “Crosslink between calcium and sodium signaling,” Exp. Physiol., 103, No. 2, 157–169 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. M. W. Jann and J. H. Slade, “Antidepressant agents for the treatment of chronic pain and depression,” Pharmacotherapy, 27, 1571–1587 (2007).

    Article  CAS  PubMed  Google Scholar 

  13. P. Kumar, G. N. Rao, B. B. Pal, and A. Pal, “Hyperglycemia-induced oxidative stress induces apoptosis by inhibiting PI3-kinase/Akt and ERK1/2 MAPK mediated signaling pathway causing downregulation of 8-oxoGDNA glycosylase levels in glial cells,” Int. J. Biochem. Cell. Biol., 53, 302–319 (2014).

    Article  CAS  PubMed  Google Scholar 

  14. F. J. Gonzalez, “Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1,” Mutat. Res., 569, Nos. 1/2, 101–110 (2005).

    Article  CAS  PubMed  Google Scholar 

  15. S. V. Bhagwat, M. R. Boyd, and V. Ravindranath, “Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria,” Biochem. Pharmacol., 59, No. 5, 573–582 (2000).

    Article  CAS  PubMed  Google Scholar 

  16. F. Seifar, M. Khalili, H. Khaledyan, et al., “α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review,” Nutr. Neurosci., 22, No. 5, 306–316 (2019), doi:https://doi.org/10.1080/1028415X.2017.1386755. Epub 2017 Nov 29.

    Article  CAS  PubMed  Google Scholar 

  17. G. Sergi, S. Pizzato, F. Piovesan, et al., “Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders,” Aging. Clin. Exp. Res., 30, No. 2, 133–138 (2018).

    Article  CAS  PubMed  Google Scholar 

  18. B. Picconi, I. Barone, A. Pisani, et al., “Acetyl-L-carnitine protects striatal neurons against in vitro ischemia: the role of endogenous acetylcholine,” Neuropharmacology, 50, No. 8, 917–923 (2006).

    Article  CAS  PubMed  Google Scholar 

  19. N. Braidy, R. Grant, and P. S. Sachdev, “Nicotinamide adenine dinucleotide and its related precursors for the treatment of Alzheimer’s disease,” Curr. Opin. Psychiat., 31, No. 2, 160–166 (2018).

    Article  Google Scholar 

  20. S. Nesci, F. Trombetti, V. Ventrella, et al., “The inhibition of the mitochondrial F1FO-ATPase activity when activated by Ca2+ opens new regulatory roles for NAD,” Biol. Chem., 399, No. 2, 197–202 (2018).

    Article  CAS  PubMed  Google Scholar 

  21. T. Kuchmerovska, I. Shymanskyy, S. Chlopicki, and A. Klimenko, “1-Methylnicotinamide (MNA) in prevention of diabetes-associated brain disorders,” Neurochem. Int., 56, 221–228 (2010).

    Article  CAS  PubMed  Google Scholar 

  22. I. P. Abita, R. Chicheportiche, and M. Schweitz, “Effect of neurotoxins (veratridine, sea anemone toxin, tetrodotoxin) on transmitter accumulation. Release by nerve terminals in vitro,” Biochemistry, 16, 1838–1864 (1977).

    Article  CAS  PubMed  Google Scholar 

  23. C. P. LeBel, H. Ischiropoulos, and S. C. Bondy, “Evaluation of the probe 2’,7’-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress,” Chem. Res. Toxicol., 5, 227–231 (1992).

    Article  CAS  PubMed  Google Scholar 

  24. A. Baracca, G. Sgarbi, G. Solaini, and G. Lenaz, “Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F0 during ATP synthesis,” Biochim. Biophys. Acta., 1606, Nos. 1/3, 137-146 (2003).

    Article  CAS  PubMed  Google Scholar 

  25. W. B. Rathbun and M. V. Betlach, “Estimation of enzymatically produced orthophosphate in the presence of cysteine and adenosine triphosphate,” Anal. Biochem., 28, 436–445 (1969).

    Article  CAS  PubMed  Google Scholar 

  26. H. U. Bergmeyer, Methods of Enzymatic Analysis, Academic Press, New York, London, Vol. 4 (1974).

    Google Scholar 

  27. O. W. Lowry, N. J. Rosebrough, R. L. Farr, and R. J. Randall, “Protein measurement with the Folin reagent,” J. Biol. Chem., 193, 265–275 (1951).

    CAS  PubMed  Google Scholar 

  28. M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” Anal. Biochem., 72, 248–254 (1976).

    Article  CAS  PubMed  Google Scholar 

  29. T. Kuchmerovska, I. Shymanskyy, G. Donchenko, et al., “Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy,” J. Diabetes Complications, 18, No. 4, 198–204 (2004).

    Article  PubMed  Google Scholar 

  30. M. R. Lakshman, M. Garige, M. A. Gong, et al., “CYP2E1, oxidative stress, post-translational modifications and lipid metabolism,” Subcell. Biochem., 67, 199–233 (2013).

    Article  CAS  PubMed  Google Scholar 

  31. A. S. Pivovarov, F. Calahorro, and R. J. Walker, “Na+/K+-pump and neurotransmitter membrane receptors,” Invert. Neurosci., 19, No. 1, 1 (2019), doi: https://doi.org/10.1007/s10158-018-0221-7

    Article  CAS  Google Scholar 

  32. T. Feldmann, M. Shahar, A. Baba, et al., “The Na(+)/Ca(2+)-exchanger: an essential component in the mechanism governing cardiac steroid-induced slow Ca(2+) oscillations,” Cell Calcium, 50, No. 5, 424–432 (2011).

    Article  CAS  PubMed  Google Scholar 

  33. M. M. Guzyk, A. A. Tykhomyrov, V. S. Nedzvetsky, et al., “Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors reduce reactive gliosis and improve angiostatin levels in retina of diabetic rats,” Neurochem. Res., 41, No. 10, 2526–2537 (2016).

    Article  CAS  PubMed  Google Scholar 

  34. M. M. Guzyk, K. O. Dyakun, L.V. Yanytska, et al., “Inhibitors of poly(ADP-ribose) polymerase-1 as agents providing correction of brain dysfunctions induced by experimental diabetes,” Neurophysiology,49, No. 3, 183–193 (2017).

    Article  CAS  Google Scholar 

  35. R. C. Scaduto Jr. and L. W. Grotyohann, “Measurement of mitochondrial membrane potential using fluores-cent rhodamine derivatives,” Biophys. J., 76, No. 1, 469–477 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. M. M. Guzyk, K. O. Dyakun, L. V. Yanitska, and Т. М. Kuchmerovska, “Influence of poly(ADP-ribose) polymerase inhibitors on some parameters of oxidative stress in blood leukocytes of rats with experimental diabetes,” Ukr. Biochem. J., 85, No. 1, 62–70 (2013).

    Article  Google Scholar 

  37. R. Castañeda-Arriaga and J. R. Alvarez-Idaboy, “Lipoic acid and dihydrolipoic acid. A comprehensive theoretical study of their antioxidant activity supported by available experimental kinetic data,” J. Chem. Inform. Model., 54, No. 6, 1642–1652 (2014).

    Article  CAS  Google Scholar 

  38. I. C. Fernandez, M. Del Carmen Camberos, G. A. Passicot, et al., “Children at risk of diabetes type 1. Treatment with acetyl-L-carnitine plus nicotinamide – case reports,” J. Pediatr. Endocrinol. Metab., 26, Nos. 3/4, 347–355 (2013).

    PubMed  Google Scholar 

  39. M. J. Clausen and H. Poulsen, “Sodium/potassium homeostasis in the cell,” Met. Ions Life Sci., 12, 41–67 (2013).

    Article  PubMed  Google Scholar 

  40. G. E. Torres and S. G. Amara, “Glutamate and monoamine transporters: new visions of form and function,” Curr. Opin. Neurobiol., 17, No. 3, 304–312 (2007).

    Article  CAS  PubMed  Google Scholar 

  41. H. P. Hammes, X. Du, D. Edelstein, et al., “Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy,” Nat. Med., 9, No. 3, 294–299 (2003).

    Article  CAS  PubMed  Google Scholar 

  42. T. Kuchmerovska, I. Shymanskyy, L. Bondarenko, and A. Klimenko, “Effects of nicotinamide supplementation on liver and serum contents of amino acids in diabetic rats,” Eur. J. Med. Res., 13, No. 6, 275–280 (2008).

    CAS  PubMed  Google Scholar 

  43. C. C. Shen, H. M. Huang, H. C. Ou, et al., “Protective effect of nicotinamide on neuronal cells under oxygen and glucose deprivation and hypoxia/reoxygenation,” J. Biomed. Sci., 11, No. 4, 472–481 (2004).

    Article  CAS  PubMed  Google Scholar 

  44. J. Luo, A. Y. Nikolaev, S. Imai, et al., “Negative control of p53 by Sir2alpha promotes cell survival under stress,” Cell, 107, No. 2, 137–148 (2001).

    Article  CAS  PubMed  Google Scholar 

  45. M. M. Guzyk, T. M. Tykhonenko, K. O. Dyakun, et al., “Altered sirtuins 1 and 2 expression in the brain of rats induced by experimental diabetes and the ways of its correction,” Ukr. Biochem. J., 91, No. 1, 21–29 (2019).

    Article  CAS  Google Scholar 

  46. J. S. Ungerstedt, M. Blomback, T. Soderstrom, “Nicotinamide is a potent inhibitor of proinflammatory cytokines,” Clin. Exp. Immunol., 131, No. 1, 48–52 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. E. Turunc Bayrakdar, Y. Uyanikgil, L. Kanit, et al., “Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aβ(1-42)-induced rat model of Alzheimer’s disease,” Free Radic. Res., 48, No. 2, 146–158 (2014).

    Article  CAS  PubMed  Google Scholar 

  48. G. Traina, “The neurobiology of acetyl-L-carnitine,” Front. Biosci. (Landmark Ed.), 21, 1314–1329 (2016).

    Article  CAS  Google Scholar 

  49. D. Ziegler, P. A. Low, and W. J. Litchy, “Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial,” Diabetes Care, 34, No. 9, 2054–2060 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. T. M. Kuchmerovskaya, P. K. Parhomets, G. V. Chichkovskaya, et al., “Nature of the brain synaptic membranes that bind nicotinamide adenine dinucleotide,” Neurochemistry,4, No. 4, 373–378 (1985).

    CAS  Google Scholar 

  51. L. J. Yan, “Redox imbalance stress in diabetes mellitus: Role of the polyol pathway,” Anim. Model Exp. Med., 1, No. 1, 7–13 (2018).

    Article  Google Scholar 

  52. W. H. Tang, K. A. Martin, and J. Hwa, “Aldose reductase, oxidative stress, and diabetes mellitus,” Front. Pharmacol., 3, 87–94 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. G. C. Ferreira and M. C. McKenna, “L-Carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain,” Neurochem. Res., 46, No. 6, 1661–1675 (2017).

    Article  CAS  Google Scholar 

  54. T. Aureli, M. E. Di Cocco, C. Puccetti, et al., “Acetyl-Lcarnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain,” Brain Res., 796, Nos. 1/2, 75–81 (1998).

    Article  CAS  PubMed  Google Scholar 

  55. G. C. Ferreira and M. C. McKenna, “L-Carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain,” Neurochem. Res., 42, No. 6, 1661–1675 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. T. M. Hagen, J. Liu, J. Lykkesfeldt, et al., “Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress,” Proc. Natl. Acad. Sci. USA, 99, No. 4, 1870–1875 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. H. Schupke, R. Hempel, G. Peter, et al., “New metabolic pathways of alpha-lipoic acid,” Drug Metab. Dispos., 29, No. 6, 855–862 (2001).

    CAS  PubMed  Google Scholar 

  58. M. Sinha, A. Bir, A. Banerjee, et al., “Multiple mechanisms of age-dependent accumulation of amyloid beta protein in rat brain: Prevention by dietary supplementation with N-acetylcysteine, α-lipoic acid and α-tocopherol,” Neurochem. Int., 95, 92–99 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Palladin Institute of Biochemistry, NAS of Ukraine, Kyiv, Ukraine

    T. M. Kuchmerovska, K. O. Dyakun & M. M. Guzyk

  2. Bogomolets National Medical University, Ministry of Public Health of Ukraine, Kyiv, Ukraine

    L. V. Yanytska

  3. Gorbachevsky Ternopil’ State Medical University, Ministry of Public Health of Ukraine, Ternopil, Ukraine

    I. B. Pryvrotska

Authors
  1. T. M. Kuchmerovska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. O. Dyakun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. M. Guzyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. V. Yanytska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. B. Pryvrotska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. M. Kuchmerovska.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuchmerovska, T.M., Dyakun, K.O., Guzyk, M.M. et al. Effects of a Combined Mitochondria-Targeted Treatment on the State of Mitochondria and Synaptic Membranes from the Brains of Diabetic Rats. Neurophysiology (2019). https://doi.org/10.1007/s11062-019-09816-6

Download citation

  • Received:

  • Published:

  • DOI: https://doi.org/10.1007/s11062-019-09816-6

Keywords

Search

Navigation